Published in Cancer on June 01, 2008
Survival after lumpectomy and mastectomy for early stage invasive breast cancer: the effect of age and hormone receptor status. Cancer (2013) 3.75
Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. J Natl Cancer Inst (2010) 3.24
Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst (2010) 2.45
Breast cancer among the oldest old: tumor characteristics, treatment choices, and survival. J Clin Oncol (2010) 2.45
A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol (2009) 2.33
Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst (2010) 2.10
Considerations for observational research using large data sets in radiation oncology. Int J Radiat Oncol Biol Phys (2014) 2.06
Cause of death in older men after the diagnosis of prostate cancer. J Am Geriatr Soc (2008) 2.01
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol (2014) 1.62
Assessing performance trends in laparoscopic nephrectomy and nephron-sparing surgery for localized renal tumors. Urology (2012) 1.54
Clinical characteristics associated with treatment type for localized renal tumors: implications for practice pattern assessment. Urology (2013) 1.49
Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer (2010) 1.41
The influence of nativity and neighborhoods on breast cancer stage at diagnosis and survival among California Hispanic women. BMC Cancer (2010) 1.23
Big data are coming to psychiatry: a general introduction. Int J Bipolar Disord (2015) 1.19
High-risk prostate cancer-classification and therapy. Nat Rev Clin Oncol (2014) 1.18
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. J Geriatr Oncol (2013) 1.16
Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood (2011) 1.12
Fracture risk in women with breast cancer: a population-based study. J Bone Miner Res (2012) 1.03
Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women. Am J Clin Oncol (2013) 1.02
Fracture risk in men with prostate cancer: a population-based study. J Bone Miner Res (2011) 1.00
Reducing bias in the assessment of treatment effectiveness: androgen deprivation therapy for prostate cancer. Med Care (2012) 0.98
Does partial nephrectomy result in a durable overall survival benefit in the Medicare population? J Urol (2012) 0.96
Outcomes following local therapy for early-stage breast cancer in non-trial populations. Breast Cancer Res Treat (2010) 0.92
Impact of breast cancer subtypes on 3-year survival among adolescent and young adult women. Breast Cancer Res (2013) 0.88
Individualized Absolute Risk Calculations for Persons with Multiple Chronic Conditions: Embracing Heterogeneity, Causality, and Competing Events. Int J Stat Med Res (2016) 0.85
Sociodemographic disparities in differentiated thyroid cancer survival among adolescents and young adults in california. Thyroid (2015) 0.83
The value of observational cohort studies for cancer drugs. Biotechnol Healthc (2010) 0.83
Impact of Treatment and Insurance on Socioeconomic Disparities in Survival after Adolescent and Young Adult Hodgkin Lymphoma: A Population-Based Study. Cancer Epidemiol Biomarkers Prev (2016) 0.82
Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab. Cancer Invest (2011) 0.81
Evaluating comparative effectiveness with observational data: endoscopic ultrasound and survival in pancreatic cancer. Cancer (2013) 0.81
Survival following non-small cell lung cancer among Asian/Pacific Islander, Latina, and Non-Hispanic white women who have never smoked. Cancer Epidemiol Biomarkers Prev (2011) 0.80
Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care (2014) 0.80
Survival after partial breast brachytherapy in elderly patients with nonmetastatic breast cancer. Brachytherapy (2013) 0.76
A Population-Based Observational Study of First-Course Treatment and Survival for Adolescent and Young Adult Females with Breast Cancer. J Adolesc Young Adult Oncol (2013) 0.76
Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know? Biomed Res Int (2016) 0.75
Did the addition of concomitant chemotherapy to radiotherapy improve outcomes in hypopharyngeal cancer? A population-based study. Curr Oncol (2016) 0.75
Does radiotherapy still have a role in unresected biliary tract cancer? Cancer Med (2016) 0.75
Nephron Sparing Surgery Has Better Oncologic Outcomes Than Extirpative Nephrectomy in T1a but Not in T1b or T2 Stage Renal Cell Carcinoma. Med Sci Monit (2017) 0.75
A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis (1987) 174.79
FUNCTIONAL EVALUATION: THE BARTHEL INDEX. Md State Med J (1965) 38.57
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
A comparison of observational studies and randomized, controlled trials. N Engl J Med (2000) 14.11
Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol (1993) 13.16
Self-rated health: a predictor of mortality among the elderly. Am J Public Health (1982) 12.18
Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med (1990) 11.57
Variable selection for propensity score models. Am J Epidemiol (2006) 10.68
Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care (1993) 9.72
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med (1997) 8.72
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Risk factors for 5-year mortality in older adults: the Cardiovascular Health Study. JAMA (1998) 8.21
Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA (2006) 8.16
Matching using estimated propensity scores: relating theory to practice. Biometrics (1996) 6.73
Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization. JAMA (2001) 6.02
The effectiveness of adjustment by subclassification in removing bias in observational studies. Biometrics (1968) 5.54
Bias and causal associations in observational research. Lancet (2002) 5.36
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys (2001) 3.70
Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst (2001) 3.65
Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology (2005) 3.58
Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol (2005) 3.33
Risk of pelvic fractures in older women following pelvic irradiation. JAMA (2005) 3.26
Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol (2006) 3.08
Estimating treatment benefits for the elderly: the effect of competing risks. Ann Intern Med (1996) 2.90
Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol (2005) 2.85
Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol (1997) 2.75
The predictive value of self assessed general, physical, and mental health on functional decline and mortality in older adults. J Epidemiol Community Health (2000) 2.65
Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis. J Clin Oncol (2001) 2.37
The use of the propensity score for estimating treatment effects: administrative versus clinical data. Stat Med (2005) 2.31
Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. J Clin Oncol (2001) 2.17
Gender differences in the self-rated health-mortality association: is it poor self-rated health that predicts mortality or excellent self-rated health that predicts survival? Gerontologist (2003) 2.17
Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol (2002) 2.12
Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol (2005) 2.11
Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol (2005) 2.10
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer. J Clin Oncol (2002) 2.09
Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol (2002) 1.93
Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol (2002) 1.93
Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med (2002) 1.89
Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci (2005) 1.73
Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol (2004) 1.68
Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer (2001) 1.56
Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol (2003) 1.41
Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol (2002) 1.34
Global self-rated health data from a longitudinal study predicted mortality better than comparative self-rated health in old age. J Clin Epidemiol (2005) 1.28
The effect of laparoscopy on survival in pancreatic cancer. Arch Surg (2002) 1.06
Pitfalls in nonrandomized outcomes studies. The case of incidental appendectomy with open cholecystectomy. JAMA (1995) 0.99
Systematic reviews incorporating evidence from nonrandomized study designs: reasons for caution when estimating health effects. Eur J Clin Nutr (2005) 0.95
The declining use of axillary dissection in patients with early stage breast cancer. Breast Cancer Res Treat (1999) 0.88
Patterns and outcomes of chemotherapy for elderly patients with stage II ovarian cancer: a population-based study. Gynecol Oncol (2004) 0.85
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol (2009) 8.55
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol (2007) 7.00
Association of hospitalist care with medical utilization after discharge: evidence of cost shift from a cohort study. Ann Intern Med (2011) 6.93
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med (2011) 6.21
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Growth in the care of older patients by hospitalists in the United States. N Engl J Med (2009) 6.14
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist (2009) 6.00
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res (2009) 5.68
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol (2009) 5.64
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Intern Med (2011) 4.98
Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 4.91
Breast carcinoma in men: a population-based study. Cancer (2004) 4.88
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA (2011) 4.63
Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med (2015) 4.53
Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med (2010) 4.52
IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell (2007) 4.48
Use of SEER-Medicare data for measuring cancer surgery. Med Care (2002) 4.27
Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell (2004) 4.17
Studying radiation therapy using SEER-Medicare-linked data. Med Care (2002) 4.13
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol (2009) 4.05
Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol (2005) 4.03
Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol (2007) 3.93
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Trastuzumab in the treatment of breast cancer. N Engl J Med (2005) 3.86
Bone imaging in metastatic breast cancer. J Clin Oncol (2004) 3.85
Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol (2005) 3.83
The effect of obesity on disability vs mortality in older Americans. Arch Intern Med (2007) 3.68
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol (2006) 3.58
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer (2005) 3.56
Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res (2007) 3.53
Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol (2006) 3.52
Association between cholecystectomy with vs without intraoperative cholangiography and risk of common duct injury. JAMA (2013) 3.52
Mammography before diagnosis among women age 80 years and older with breast cancer. J Clin Oncol (2008) 3.49
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol (2007) 3.46
Male breast cancer. Lancet (2006) 3.41
Breast cancer in men. Ann Intern Med (2002) 3.39
Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol (2006) 3.34
Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst (2008) 3.17
Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med (2003) 3.11
Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst (2006) 3.10
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol (2008) 3.09
Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med (2010) 3.09
Overuse of screening colonoscopy in the Medicare population. Arch Intern Med (2011) 3.08
Use and outcomes of adjuvant chemotherapy in older women with breast cancer. J Clin Oncol (2006) 3.08
Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol (2012) 2.98
Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst (2005) 2.93
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol (2007) 2.90
Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency. Clin Cancer Res (2007) 2.89
Neighborhood context and mortality among older Mexican Americans: is there a barrio advantage? Am J Public Health (2004) 2.87
Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol (2006) 2.84
Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 2.75
Is breast cancer survival improving? Cancer (2004) 2.73
High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol (2011) 2.73
Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol (2005) 2.69
Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res (2002) 2.66
Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. Clin Cancer Res (2011) 2.64
Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst (2007) 2.60
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol (2010) 2.52
Long-term complications associated with breast-conservation surgery and radiotherapy. Ann Surg Oncol (2002) 2.51
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. Mol Cancer Ther (2011) 2.50
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol (2008) 2.43
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008) 2.42
Relationship between obesity and pathologic response to neoadjuvant chemotherapy among women with operable breast cancer. J Clin Oncol (2008) 2.40
Delivering high-quality and affordable care throughout the cancer care continuum. J Clin Oncol (2013) 2.39
Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol (2005) 2.39
Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol (2011) 2.32
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res (2013) 2.30
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res (2008) 2.29
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J Clin Oncol (2011) 2.29
Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Res (2010) 2.26